Medicine and Dentistry
Anakinra
100%
Serositis
100%
Tocilizumab
100%
Severe Acute Respiratory Syndrome Coronavirus 2
100%
Pediatrics
100%
Immunoglobulin
100%
Methylprednisolone
66%
Coronary Artery Aneurysm
33%
Monoclonal Antibody
33%
Anti-Inflammatory Drug
33%
Single Drug Dose
33%
Receptor
33%
Interleukin-6
33%
Medical Research
33%
Cardiac Dysrhythmia
33%
Receptor Antagonist
33%
Bleeding
33%
Interleukin-1
33%
Keyphrases
PIMS-TS
100%
Pediatric Inflammatory multisystem Syndrome Temporally Associated with SARS-CoV-2
100%
Platform Trials
100%
Multisystem Inflammatory Syndrome in children (MIS-C)
100%
Immunomodulatory Therapy
100%
Usual Care
100%
Length of Hospital Stay
50%
Anakinra
30%
Intravenous Immunoglobulin (IVIg)
30%
Initial Treatment
20%
Tocilizumab
20%
Methylprednisolone
20%
Inflammation
20%
Coronary Artery Aneurysm
10%
Intravenous Tocilizumab
10%
Anti-IL-6 Receptor Monoclonal Antibodies
10%
Intravenous Corticosteroids
10%
Bleeding Events
10%
Ventricular Arrhythmia
10%
Pediatric
10%
18 Years Old
10%
Consecutive Days
10%
Additional Treatment
10%
Health Research
10%
Interleukin-1 Receptor Antagonist (IL-1Ra)
10%
Thrombotic Events
10%
Day Care
10%
RECOVERY Trial
10%
Anti-inflammatory Therapy
10%
Posterior Probability
10%
Medical Research Council
10%
National Institutes of Health
10%
Anti-IL-1
10%
